Table 2: rSBA-MenC antibody response after Hib-MenC-TT vaccination.

ReferencePrimary vaccinationBooster vaccinationTimepoint 𝑁 rSBA-MenC ≥1 : 8rSBA-MenC ≥1 : 128GMT
%[95% CI]%[95% CI]Value[95% CI]

Schmitt et al., 2007 [70] 2, 3, 4 + 12–15 months of ageHib-MenC-TT + DTPa-HBV-IPVMen-PS + DTPa-HBV-IPV/HibPD395100[96.2–100]944.2[779.4–1143.8]
Pre-Ch9087.1[78.0–93.4]159.3[107.9–235.3]
Post-Ch83100[95.5–100]5385.4[4425.0–5554.2]
MenC-CRM197 + DTPa-HBV-IPV/HibMen-PS + DTPa-HBV-IPV/HibPD3105100[96.5–100]1400.7[1165.4–1683.5]
Pre-Ch9380.2[70.6–87.8]104.0[68.4–158.3]
Post-Ch8696.5[90.0–99.3]1552.6[1044.4–2307.9]

Pace et al., 2007 & 2008 [69, 73] Khatami et al., 2011 [76] 2, 3, 4 + 12–15 months of ageHib-MenC-TT + DTPa-IPVHib-MenC-TT + MMRPD335499.2[97.5–99.8]92.9[89.8–95.4]581.1[514.7–656.2]
Pre-B34678.0[73.3–82.3]43.9[38.6–49.3]61.3[50.9–73.7]
Post-B34799.1[97.5–99.8]97.7[95.5–99.0]2193.7[1881.1–2558.1]
Post-B (Y1)20089.0[83.8–93.0]54.5[47.3–61.5]123.0[98.9–153.0]
Post-B (Y2)21967.1[60.5–73.3]39.3[32.8–46.1]48.0[36.8–62.6]
MenC-CRM197 + DTPa-IPV/HibHib-MenC-TT + MMRPD3117100[96.9–100]91.1[95.3–100]1002.6[833.8–1205.6]
Pre-B10967.9[58.3–76.5]33.0[24.3–42.7]38.6[27.5–54.2]
Post-B11495.6[90.1–98.6]86.0[78.2–91.8]477.9[357.3–639.2]
Post-B (Y1)5969.5[56.1–80.8]28.8[17.8–42.1]35.7[23.4–54.5]
Post-B (Y2)7440.5[29.3–52.6]13.5[6.7–23.5]14.4[9.7–21.6]

Tejedor et al., 2007 & 2008 [62, 74] 2, 4, 6 + 13–14 months of ageHib-MenC-TT + DTPa-HBV-IPVHib-MenC-TTPD3111100[96.7–100]99.195.1–1002467.1[2045.7–2975.3]
Pre-B8196.3[89.6–99.2]84.074.1–91.2366.1[270.1–496.2]
Post-B81100[95.5–100]100[95.5–100]5266.2[4265.6–6501.3]
Post-B (Y1)5687.5[75.9– 94.8]94.0[59.8–147.9]
MenC-TT + DTPa/Hib-containingHib-MenC-TTPD2107100[96.6–100]98.1[93.4–99.8]1542.9[1282.2–1856.5]
Pre-B16990.5[85.1–94.5]59.8[52.0–67.2]131.0[103.5–165.6]
Post-B16799.4[96.7–100]99.4[96.7–100]11710.0[9441.5–14524.8]
Post-B (Y1)12195.0[89.5–98.2]293.8[212.8–405.7]
MenC-CRM197 + DTPa-HBV-IPV/HibDTPa-HBV-IPV/HibPD311499.1[95.2–100]98.293.8–99.81833.7[1493.7–2251.0]
Pre-B8285.4[75.8–92.2]56.144.7–67.0120.5[80.2–180.9]
Post-B8477.4[67.0–85.8]56.0[44.7–66.8]94.1[59.6–148.7]

Carmona et al., 2010 [75] 2, 4, 6 + 13–14 months of ageMenC-CRM197 + DTPa/Hib-containingHib-MenC-TT + MMRPre-B*9388.2[79.8–93.9]46.2[35.8–56.9]103.8[74.2–145.1]
Post-B9598.9[94.3–100]89.5[81.5–94.8]670.2[497.9–902.1]
MenC-CRM197 + DTPa/Hib-containingHib-MenC-TTPre-B*9485.1[76.3–91.6]56.4[45.8–66.6]107.1[74.1–154.7]
Post-B9598.9[94.3–100]92.6[85.4–97.0]685.0[527.0–890.4]

Habermehl et al., 2010 [68] 2, 3, 4 + 12–18 monthsHib-MenC-TT + DTPa-HBV-IPVHib-MenC-TT + DTPa-HBV-IPVPD374100[95.1–100]95.9[88.6–99.2]871.0[677.3–1120.0]
Pre-B*4195.1[83.5–99.4]65.9[49.4–79.9]150.6[96.7–234.5]
Post-B41100[91.4–100]97.6[87.1–99.9]3226.2[2294.7–4535.8]
MenC-CRM197 + DTPa-HBV-IPV/HibMenC-CRM197 + DTPa-HBV-IPV/HibPD371100[94.9–100]100[94.9–100]3557.6[2978.8–4248.8]
Pre-B*3894.7[82.3–99.4]68.4[51.3–82.5]195.5[122.4–312.2]
Post-B39100[91.0–100]100[91.0–100]11819.3[8458.6–16515.2]

Knuf et al., 2009 [71] 2, 4, 6 + 11–18 months of ageHib-MenC-TT + PHiD-CV + DTPa-HBV-IPVHib-MenC-TT + PHiD-CV + DTPa-HBV-IPVPD3137100[97.3–100]97.1[92.7–99.2]1590.9[1298.5–1949.1]
Post-B79100[95.4–100]100[95.4–100]5099.2[3940.4–6598.9]
Hib-MenC-TT + 7vCRM + DTPa-HBV-IPVHib-MenC-TT + 7vCRM + DTPa-HBV-IPVPD312099.2[95.4–100]95.0[89.4–98.1]1207.7[964.4–1512.3]
Post-B76100[95.3–100]97.4[90.8–99.7]3269.8[2489.7–4294.4]
MenC-TT + DTPa-HBV-IPV/Hib + PHiD-CV MenC-TT + DTPa/Hib-containing + PHiD-CV PD2177100[97.9–100]97.2[93.5–99.1]1474.2[1263.3–1 720.4]
Post-B 84100[95.7–100]100[95.7–100]4587.8[3763.1–5593.2]
MenC-CRM197 + DTPa-HBV-IPV/Hib + PHiD-CV MenC-CRM197 + DTPa/Hib-containing + PHiD-CV PD216598.8[95.7–99.9]97.0[93.1–99.0]1299.8[1082.0–1561.5]
Post-B89100[95.9–100]98.9[93.9–100]2779.6[2198.5–3514.2]

Booy et al., 2011 [72]12–18 months3xDTPa/Hib-TT or2xHib-OMPHib-MenC-TT + MMRPre-Vac25514.5[10.4–19.4]5.9[3.3–9.5]6.3[5.5–7.3]
Post-Vac28199.6[98.0–100]87.9[83.5–91.5]482.8[420.7–554.2]
Post-Vac (Y1)24986.7[81.9–90.7]47.0[40.7–53.4]91.7[75.6–111.3]
3xDTPa/Hib-TT or 2xHib-OMPHib-TT + MenC-CRM197 + MMRPre-Vac838.4[3.5–16.6]3.6[0.8–10.2]5.5[4.3–7.2]
Post-Vac98100[96.3–100]90.8[83.3–95.7]621.0[480.3–802.9]
Post-Vac (Y1)8976.4[66.2–84.8]41.6[31.2–52.5]63.8[43.3–94.1]

𝑁 : numbers of subjects with available data, %: percentage of subjects with titre within the specified range, 95% CI: 95% confidence interval, GMT: Geometric Mean Titre, PD2: one month after dose 2 (Primary ATP cohort for immunogenicity), PD3: one month after dose 3 (Primary ATP Cohort for Immunogenicity), Pre-Ch: just prior to meningococcal polysaccharide challenge (ATP Cohort for Persistence), Post-Ch: one month after meningococcal polysaccharide challenge (ATP Cohort for Immunogenicity), Pre-B: just prior to the booster vaccination (ATP Cohort for Persistence), Pre-B*: just prior to the booster vaccination (ATP Cohort for Immunogenicity), Post-B: one month after booster vaccination (Booster ATP Cohort for Immunogenicity), Post-B (Y1): one year after booster vaccination (ATP Cohort for Persistence Year 1), Post-B (Y2): two years after booster vaccination (ATP Cohort for Persistence Year 1), Pre-Vac: just prior to the vaccination (Vaccination ATP cohort for Immunogenicity), Post-Vac: one month after vaccination (Vaccination ATP cohort for Immunogenicity), Post-Vac (Y1): one year after vaccination (ATP cohort for Persistence Year 1), Results of this table were previously published [62, 6876].